These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 26035698)

  • 1. MiR-320e is a novel prognostic biomarker in colorectal cancer.
    Perez-Carbonell L; Sinicrope FA; Alberts SR; Oberg AL; Balaguer F; Castells A; Boland CR; Goel A
    Br J Cancer; 2015 Jun; 113(1):83-90. PubMed ID: 26035698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer.
    Imaoka H; Toiyama Y; Fujikawa H; Hiro J; Saigusa S; Tanaka K; Inoue Y; Mohri Y; Mori T; Kato T; Toden S; Goel A; Kusunoki M
    Ann Oncol; 2016 Oct; 27(10):1879-86. PubMed ID: 27502702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
    Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
    Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apical Lymph Nodes in the Distant Metastases and Prognosis of Patients with Stage III Colorectal Cancer with Adequate Lymph Node Retrieval Following FOLFOX Adjuvant Chemotherapy.
    Tsai HL; Chen YT; Yeh YS; Huang CW; Ma CJ; Wang JY
    Pathol Oncol Res; 2019 Jul; 25(3):905-913. PubMed ID: 29299827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.
    Roseweir AK; Park JH; Hoorn ST; Powell AG; Aherne S; Roxburgh CS; McMillan DC; Horgan PG; Ryan E; Sheahan K; Vermeulen L; Paul J; Harkin A; Graham J; Sansom O; Church DN; Tomlinson I; Saunders M; Iveson TJ; Edwards J
    J Pathol Clin Res; 2020 Oct; 6(4):283-296. PubMed ID: 32401426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring microRNA patterns as biomarkers of FOLFOX chemotherapy-induced peripheral neuropathy in patients with colorectal cancer.
    Ju Y; Baek DH; Choi GE; Jang A
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167209. PubMed ID: 38701955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
    Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T
    BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
    Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
    Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study.
    Gormley JA; Hegarty SM; O'Grady A; Stevenson MR; Burden RE; Barrett HL; Scott CJ; Johnston JA; Wilson RH; Kay EW; Johnston PG; Olwill SA
    Br J Cancer; 2011 Nov; 105(10):1487-94. PubMed ID: 21989182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial DNA Copy Number as a Biomarker for Guiding Adjuvant Chemotherapy in Stages II and III Colorectal Cancer Patients with Mismatch Repair Deficiency: Seeking Benefits and Avoiding Harms.
    Chen M; Deng S; Cao Y; Wang J; Zou F; Gu J; Mao F; Xue Y; Jiang Z; Cheng D; Huang N; Huang L; Cai K
    Ann Surg Oncol; 2024 Sep; 31(9):6320-6330. PubMed ID: 38985229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer.
    Hur K; Toiyama Y; Schetter AJ; Okugawa Y; Harris CC; Boland CR; Goel A
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.